Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease

Duo Using Curadev’s Stimulator Of Interferon Genes Antagonist Platform

Executive Summary

Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.

You may also be interested in...



Bayer Back In M&A Mode To Boost Pipeline

The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel